Core Points - LifeMD, Inc. has rescheduled its third quarter 2025 earnings release and conference call to November 17, 2025, due to identified corrections in revenue recognition [1][2] - The cumulative impact of these corrections is approximately $4.6 million, representing about 1.4% of cumulative revenue reported for the twelve months ended December 31, 2024, and six months ended June 30, 2025 [2] - The adjustments will not materially affect reported revenue results compared to guidance for the relevant reporting periods and will not impact the company's cash flow or cash position [2] Earnings Release Details - The earnings press release is expected to be issued around 4:05 p.m. Eastern time on November 17, 2025, followed by a conference call at 4:30 p.m. Eastern time [3] - Conference call details include a toll-free dial-in number (800-245-3047), an international dial-in number (203-518-9765), and a conference ID (LIFEMD) [3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [4] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [4]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects and competitive position during a specified period in 2025 [1][2]. Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The statements made by the defendants regarding LifeMD's business operations and prospects were claimed to be materially false and misleading [2]. Financial Impact - Following the announcement of its second quarter 2025 results, which included a revision of full-year guidance due to "temporary challenges" in the RexMD business, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 27, 2025, although they can remain absent class members without taking action [4].

Core Insights - LifeMD, Inc. has appointed Shayna Webb Dray as Chief Operating Officer, recognizing her extensive experience in operations and supply chain management [1][2] - The company aims to leverage Ms. Webb Dray's leadership to enhance growth in new verticals and improve patient care quality [2] - LifeMD has also expanded the roles of other executives, including Jessica Friedeman as Chief Marketing and Product Officer and Jacob Ellison as Chief Analytics Officer [3][4] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory, and pharmacy services across more than 200 conditions [4] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art pharmacy to provide high-quality and affordable care [4]